Meeting
2024 ASCO Genitourinary Cancers Symposium
Impact of renin-angiotensin system inhibitors on response to PD1/L1 inhibitors in patients with metastatic renal cell carcinoma (mRCC).
Authors
Kathryn Fortune
University of Virginia, Charlottesville, VA
Kathryn Fortune , Soham Ali , Jack Masur , Paul Vincent Viscuse , Michael Edward Devitt , Robert Dreicer , William Paul Skelton IV
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 424)
DOI
10.1200/JCO.2024.42.4_suppl.424
Abstract #
424
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A multicenter real-world study reviewing systemic anticancer treatment choices and drop off rates between treatment lines for metastatic renal cell carcinoma in the United Kingdom: In the immunotherapy era.
First Author: John McGrane
Poster
2020 Genitourinary Cancers Symposium
Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Igor Stukalin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.
First Author: Ningning Li
Poster
2023 ASCO Annual Meeting
Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Georges Gebrael